A key development in neurological care is set to benefit thousands of individuals living with Multiple Sclerosis (MS) across the UK. NHS England has officially approved routine funding for fampridine (also known by the brand name Fampyra), bringing access in line with Scotland, Wales, and Northern Ireland.
For family carers, care teams, and home care providers, this announcement marks a notable shift in symptom management, offering an oral treatment targeted directly at improving walking difficulties.
What is Multiple Sclerosis?
Multiple Sclerosis is a lifelong neurological condition that affects the central nervous system, comprising the brain and spinal cord. In people with MS, the immune system mistakenly attacks the protective coating around nerve fibers, known as myelin.
This damage disrupts the normal transmission of electrical messages between the brain and the rest of the body. As a result, individuals often experience symptoms such as severe fatigue, muscle stiffness, balance problems, and progressive difficulty with walking.
How Fampridine Works
Fampridine is the first licensed medication designed specifically to target walking impairment caused by MS.
Unlike disease-modifying therapies that focus on slowing down overall disease progression or preventing relapses, fampridine acts as a targeted potassium channel blocker.By blocking tiny channels on damaged nerve fibers, it prevents potassium from leaking out. This effectively acts as a “signal booster,” enabling electrical impulses to travel more smoothly and reliably along damaged nerves to the muscles responsible for movement.
Key Benefits for Patients and Support Networks
Taken as a twice-daily tablet, fampridine offers practical physical and daily benefits for individuals who respond to the drug:
-
Increased Walking Speed: Clinical trials demonstrate that around four in ten patients experience a significant increase in walking speed, averaging roughly a 25% improvement.
-
Greater Mobility and Stamina: Many individuals report being able to walk longer distances and navigate daily tasks with less physical exertion.
-
Enhanced Daily Independence: Better mobility translates into greater ease with personal care, household tasks, and social activities, helping individuals retain employment and community involvement.
-
Reduced Care Burden: For family members and professional care staff, improved patient mobility can lower the physical demands involved in transfers, assistance with movement, and daily routines.
Who is Eligible for Treatment?
The drug is available to adults living with any form of MS (whether relapsing or progressive) who meet specific clinical criteria:
-
Disability Level: Patients must fall within an Expanded Disability Status Scale (EDSS) score of 4.0 to 7.0. This ranges from individuals who can walk unassisted for around 500 meters to those who rely heavily on mobility aids or wheelchairs but can still walk short distances.
-
Medical Safety Screening: Patients must have healthy kidney function and no personal history of seizures or epilepsy.
-
Response Assessment: Eligible patients start on a 2 to 4-week trial period. Long-term NHS funding is continued only for individuals who show a clear, measurable improvement in walking speed during timed tests at the end of the trial.
When and How Will It Be Available?
While the drug has received official NHS recommendation in England following the expiry of its exclusive patent, rollout to individual patients will happen gradually:
-
Current Status: Fampridine is already approved across all four UK nations.
-
Rollout Timeline: Local NHS trusts, Integrated Care Boards, and specialist MS neurology clinics are currently setting up the required prescribing pathways and monitoring services. As a result, immediate access at local GP surgeries is not available; prescriptions must be initiated by specialist MS medical teams.
-
Action for Carers and Families: Families and care teams are advised to discuss fampridine eligibility with the individual’s specialist MS nurse or neurologist during their next routine review, allowing local services time to establish their assessment procedures.
